SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Item

http://www.wikidata.org/entity/Q36811227

Q36811227

about

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial Can early therapy reduce inflammation?Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Epidemiology and management of antiretroviral-associated cardiovascular disease.Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.Cardiovascular disease in human immunodeficiency virus.Switch strategies in antiretroviral therapy regimens.Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana.Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

P2860

Q28535587-F5E5F1BB-7CEA-4AF4-B808-AF52BCA6E085 Q28543732-6AA8E83F-4058-47F2-ABF9-058EFB2CC8DA Q33604322-38607121-F539-417B-909C-8081F7667C9F Q34159822-B240F762-4363-4871-9D28-71620705000E Q34478840-B785E869-C45D-48B1-A9A2-87A2D3B16832 Q35103606-9FE29E89-76A2-460E-A08F-7E4B57360744 Q35186842-0ADC4F7D-304D-41E9-9535-AD98E8736CD1 Q35338096-A68AA2EB-F59A-42BD-B41A-49B92E375994 Q36220644-88AB4E2A-0715-4763-BA48-D420C26DAC63 Q36426953-99A66416-660D-4AC7-A059-F0728337E4E6 Q37279429-B87D9C6E-CE00-40A8-A5FA-C975371E1C56 Q37296706-1B6B6ED0-3F7B-40F3-94FA-6DC0F73C25F7 Q37319195-D0E86435-E49D-446D-B6E4-75517E548092 Q38206287-2C674F3C-D66D-4F01-B9F0-07D900C9AD24 Q38235295-F617DF38-765E-4FFC-8C43-38C4E5CB1C6C Q38596011-17281317-4164-4340-B95D-4764F5366905 Q38723259-797203B8-966E-4ECD-AA55-5244CD0DFDD2 Q40100018-846675BE-B837-4AE9-8723-6B63DDB49F43 Q40395175-67413B7E-FD71-4B70-B7FC-29BD8776B6EB Q40581358-306A62F9-5195-45EB-9162-2E3BB6331F49 Q40790663-3F65209E-90C5-452E-88BA-466F6DFAF134 Q40806577-773FE5A7-C566-493B-A5F1-DAB97934720D Q57180790-34AE8E31-2EA1-46E2-8B04-2709636E9AA0

P2860

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Item

http://www.wikidata.org/entity/Q36811227

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@ast

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@en

type

Item

label

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@ast

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@en

prefLabel

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@ast

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@en

P1476

SWIFT: prospective 48-week stu ...... aining antiretroviral regimen.

@en

P2093

B Guyer

http://www.w3.org/2001/XMLSchema#string

C Brinson

http://www.w3.org/2001/XMLSchema#string

D Piontkowsky

http://www.w3.org/2001/XMLSchema#string

E DeJesus

http://www.w3.org/2001/XMLSchema#string

H Khanlou

http://www.w3.org/2001/XMLSchema#string

H Wang

http://www.w3.org/2001/XMLSchema#string

J Flaherty

http://www.w3.org/2001/XMLSchema#string

K Henry

http://www.w3.org/2001/XMLSchema#string

K Logue

http://www.w3.org/2001/XMLSchema#string

K White

http://www.w3.org/2001/XMLSchema#string

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.

Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.

Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

P304

1637-1645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS1203

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235383580

http://www.w3.org/2001/XMLSchema#string

P698

23362296

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

virology

P932

3641864

http://www.w3.org/2001/XMLSchema#string

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

about

P2860

P2860

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932